SMAD3 and skin basal cell carcinoma: This is consistent with our Smad3 ChIP-seq data in resistant BCC cells, where we observe that when AP-1 is active, Smad3 binding sites are more enriched for AP-1 motifs rather than Smad motifs (Supplementary Fig. 5e).